Immutep

Phase I

Immutep S.A. announced today that it has initiated a Phase I clinical trial of its lead product ImmuFact® IMP321 in metastatic renal cell carcinoma. This is the Company's first clinical trial targeting cancer. Immutep is already carrying out trials of IMP321 to show safety and immune response to infectious disease antigens in healthy volunteers. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response through activation of dendritic cells and more efficient antigen presentation to T cells.

Please, click on ADOBE PDF logo to read the complete communique.

Published 11/2005 by admin@immutep.com